David Rubin to Janus Kinase Inhibitors
This is a "connection" page, showing publications David Rubin has written about Janus Kinase Inhibitors.
Connection Strength
2.273
-
New Eczematous Eruption in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors. Am J Gastroenterol. 2026 Jan 01; 121(1):268-273.
Score: 0.906
-
Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
Score: 0.576
-
Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2026 Mar; 24(3):784-793.
Score: 0.225
-
Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis. 2023 09 01; 29(9):1370-1379.
Score: 0.198
-
Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Gastroenterology. 2022 12; 163(6):1555-1568.
Score: 0.184
-
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Jan 24; 12(2):145-156.
Score: 0.134
-
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024 Oct; 22(10):2096-2106.
Score: 0.051